Zacks: Brokerages Anticipate Magenta Therapeutics, Inc. (NASDAQ:MGTA) Will Announce Earnings of -$0.34 Per Share

Equities research analysts expect Magenta Therapeutics, Inc. (NASDAQ:MGTAGet Rating) to post earnings per share of ($0.34) for the current quarter, according to Zacks. Zero analysts have issued estimates for Magenta Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.37). Magenta Therapeutics posted earnings of ($0.36) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 5.6%. The firm is expected to issue its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Magenta Therapeutics will report full year earnings of ($1.43) per share for the current year, with EPS estimates ranging from ($1.55) to ($1.30). For the next year, analysts expect that the business will post earnings of ($1.45) per share, with EPS estimates ranging from ($1.65) to ($1.18). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Magenta Therapeutics.

Magenta Therapeutics (NASDAQ:MGTAGet Rating) last announced its quarterly earnings results on Tuesday, March 8th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.01).

MGTA has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Magenta Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, March 11th. B. Riley dropped their price target on shares of Magenta Therapeutics from $13.00 to $6.00 and set a “buy” rating for the company in a research report on Monday, January 24th. BTIG Research lowered their price objective on shares of Magenta Therapeutics from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Monday, April 18th. The Goldman Sachs Group upgraded shares of Magenta Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $7.00 to $8.00 in a research note on Wednesday, January 5th. Finally, Mizuho reduced their price objective on shares of Magenta Therapeutics from $17.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, April 18th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Magenta Therapeutics currently has an average rating of “Buy” and a consensus target price of $9.04.

Large investors have recently bought and sold shares of the stock. Morgan Stanley increased its stake in Magenta Therapeutics by 6,706.4% during the second quarter. Morgan Stanley now owns 59,352 shares of the company’s stock valued at $581,000 after acquiring an additional 58,480 shares during the period. Millennium Management LLC lifted its holdings in shares of Magenta Therapeutics by 47.9% during the 2nd quarter. Millennium Management LLC now owns 64,115 shares of the company’s stock worth $627,000 after acquiring an additional 20,765 shares during the period. Invesco Ltd. acquired a new stake in shares of Magenta Therapeutics during the 2nd quarter valued at about $107,000. Vontobel Holding Ltd. bought a new stake in Magenta Therapeutics in the third quarter valued at about $108,000. Finally, SG Americas Securities LLC acquired a new position in Magenta Therapeutics in the third quarter worth about $107,000. Institutional investors and hedge funds own 59.13% of the company’s stock.

MGTA stock traded down $0.09 on Friday, reaching $1.59. The company’s stock had a trading volume of 290,892 shares, compared to its average volume of 141,661. Magenta Therapeutics has a 12-month low of $1.55 and a 12-month high of $13.22. The firm has a market cap of $93.49 million, a PE ratio of -1.21 and a beta of 2.01. The business has a fifty day simple moving average of $2.81 and a two-hundred day simple moving average of $4.53.

Magenta Therapeutics Company Profile (Get Rating)

Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants.

Read More

Get a free copy of the Zacks research report on Magenta Therapeutics (MGTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Magenta Therapeutics (NASDAQ:MGTA)

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.